Linda Burkly

CIK: 0001985604

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EDIT

Editas Medicine, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

EDIT
Editas Medicine, Inc.
Sep 3, 2026
Sale(S)
Direct
709 shares at avg. $3.04$2K
EDIT
Editas Medicine, Inc.
Jul 28, 2026
Sale(S)
Direct
4.9K shares at avg. $2.67$13K
EDIT
Editas Medicine, Inc.
Jun 3, 2026
Sale(S)
Direct
731 shares at avg. $2.70$2K
EDIT
Editas Medicine, Inc.
Mar 12, 2026
Award(A)
Stock Option (right to buy)
Direct
292.9K shares-
EDIT
Editas Medicine, Inc.
Mar 3, 2026
Sale(S)
Direct
749 shares at avg. $2.02$2K
EDIT
Editas Medicine, Inc.
Dec 3, 2025
Sale(S)
Direct
713 shares at avg. $2.15$2K
EDIT
Editas Medicine, Inc.
Sep 3, 2025
Sale(S)
Direct
710 shares at avg. $2.60$2K
EDIT
Editas Medicine, Inc.
Jul 31, 2025
Sale(S)
Direct
5.1K shares at avg. $2.49$13K
EDIT
Editas Medicine, Inc.
Jun 3, 2025
Sale(S)
Direct
726 shares at avg. $1.72$1K
EDIT
Editas Medicine, Inc.
Mar 8, 2025
Award(A)
Stock Option (right to buy)
Direct
275.1K shares-
EDIT
Editas Medicine, Inc.
Mar 8, 2025
Award(A)
Stock Option (right to buy)
Direct
70K shares-
EDIT
Editas Medicine, Inc.
Mar 4, 2025
Sale(S)
Direct
2.9K shares at avg. $1.71$5K

		Type	Shares	Price		Ownership
Sep 3, 2026	EDIT Editas Medicine, Inc.	Sale(S)	709	$3.04	$2,153	Direct
Jul 28, 2026	EDIT Editas Medicine, Inc.	Sale(S)	4,928	$2.67	$13,158	Direct
Jun 3, 2026	EDIT Editas Medicine, Inc.	Sale(S)	731	$2.70	$1,975	Direct
Mar 12, 2026	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	292,856	-	-	Direct
Mar 3, 2026	EDIT Editas Medicine, Inc.	Sale(S)	749	$2.02	$1,513	Direct
Dec 3, 2025	EDIT Editas Medicine, Inc.	Sale(S)	713	$2.15	$1,535	Direct
Sep 3, 2025	EDIT Editas Medicine, Inc.	Sale(S)	710	$2.60	$1,843	Direct
Jul 31, 2025	EDIT Editas Medicine, Inc.	Sale(S)	5,121	$2.49	$12,757	Direct
Jun 3, 2025	EDIT Editas Medicine, Inc.	Sale(S)	726	$1.72	$1,252	Direct
Mar 8, 2025	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	275,100	-	-	Direct
Mar 8, 2025	EDIT Editas Medicine, Inc.	Award(A) Stock Option (right to buy)	70,000	-	-	Direct
Mar 4, 2025	EDIT Editas Medicine, Inc.	Sale(S)	2,891	$1.71	$4,946	Direct

1-12 of 12 transactions

About Burkly Linda

Burkly Linda (SEC CIK 0001985604) files insider reports with the SEC as EVP, CHIEF SCIENTIFIC OFFICER of Editas Medicine, Inc. (EDIT).

Signal8 holds 11 ownership filings by Burkly Linda, all Form 4s, filed between Mar 5, 2025 and Sep 4, 2026. Those filings report 12 transactions, from Mar 4, 2025 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Burkly Linda's filings is in CAMBRIDGE, MA.

Recent filings by Burkly Linda

Sep 3, 2026: Open-market sale of EDIT shares (Form 4, code S).
Jul 28, 2026: Open-market sale of EDIT shares (Form 4, code S).
Jun 3, 2026: Open-market sale of EDIT shares (Form 4, code S).
Mar 12, 2026: Grant or award of EDIT derivative securities (Form 4, code A).
Mar 3, 2026: Open-market sale of EDIT shares (Form 4, code S).

Other insiders filing for Editas Medicine, Inc. (EDIT)

Ory Daniel Scott, EVP, Chief Medical Officer
Parison Amy, SVP, Chief Financial Officer
O'Neill Gilmore Neil, CEO
Ellinor Patrick Thomas II, Director
Connaughton Bernadette, Director
Hopfield Jessica, Director

How to read Form 4 transaction codes